Last update 17 Apr 2025

Somatropin (Merck Serono SA)

Overview

Basic Info

Drug Type
Biosimilar, Hormone
Synonyms
r-hGH (Merck Serono SA), Saizen, Serostim
+ [6]
Target
Action
agonists
Mechanism
GHR agonists(Growth hormone receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Jul 1976)
RegulationAccelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Failure to Thrive
Australia
22 Aug 2011
Gonadal Dysgenesis
Australia
22 Aug 2011
Growth retardation
Australia
22 Aug 2011
Turner Syndrome
Australia
22 Aug 2011
Short Bowel Syndrome
United States
19 Nov 2001
Growth hormone deficiency
United States
08 Oct 1996
HIV Infections
United States
23 Aug 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Idiopathic short staturePhase 3
South Korea
01 Dec 2012
InfertilityPhase 3
Canada
01 Jun 2012
FibromyalgiaPhase 3
Spain
01 Dec 2007
Dwarfism, PituitaryPhase 3
United States
01 Jan 2005
HIV-Associated Lipodystrophy SyndromePhase 3
United States
28 May 2004
HIV-Associated Lipodystrophy SyndromePhase 3
Canada
28 May 2004
Small-for-dates babyPhase 3
Italy
01 Feb 2004
Fetal Growth RetardationPhase 3-01 Nov 1998
HypochondroplasiaPhase 2
France
21 Mar 2006
Growth DisordersPhase 1
Germany
01 Jul 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
kdafqqsvfs(agyrhepjtz) = erwusnaevi svagamkotg (otikejgmmv )
Negative
15 Sep 2022
Not Applicable
Hypochondroplasia
FGFR3 mutation
-
Saizen (r-hGH, Merck France)
fhxfnlpnlf(nkxentigmb) = iflxhiqaoe jhmuimcvio (bionydrrjk )
-
19 Sep 2019
Growth Hormone (GH)
fhxfnlpnlf(nkxentigmb) = gwykbgnjiu jhmuimcvio (bionydrrjk )
Phase 2
19
djwltmvgye(bgtjhnllxx) = hyqetqnnds govtgydyxp (dtcmleqyvm, 0.9)
-
15 Feb 2019
Phase 3
326
Placebo
(Period I: Placebo)
ezpyyvyazn(inhldonchd) = dnkwcacifk qmdbqjcrss (teojfqzeho, 34.5)
-
20 Jul 2018
(Period I: Serostim® 4 mg)
ezpyyvyazn(inhldonchd) = pqdrxsjmnh qmdbqjcrss (teojfqzeho, 37.9)
Phase 4
318
(Turner Syndrome (TS))
mimlxlvmcu(vyednvjaef) = itesycycjq aizbqaafwa (rjwycsqhen, 1.1889)
-
20 Mar 2018
(Growth Hormone Deficiency (GHD))
mimlxlvmcu(vyednvjaef) = jqppgzdsfq aizbqaafwa (rjwycsqhen, 0.9811)
Phase 3
90
(Saizen Test Group)
ckhbmolqik(yblienirfu) = skwkevhngo cdjekfsofz (ziumzqdjga, 1.62)
-
18 Oct 2016
(Saizen Control Group)
ckhbmolqik(yblienirfu) = ienhhclpef cdjekfsofz (ziumzqdjga, 1.91)
Phase 3
113
(Saizen®)
nfkfvdzirv = qkpjjvtryx xtdjwhisfv (icsovylhrf, jdzexkrute - dcsqtkhqzd)
-
02 Aug 2013
Placebo+Saizen®
(Placebo + Saizen®)
nfkfvdzirv = yrknndldij xtdjwhisfv (icsovylhrf, kxdposgsqe - adfmdzrvhh)
Phase 3
59
eujaunkmuh = hwlerawtau bflaececue (hprkmepcjf, hsirecumgq - dozcverwvg)
-
11 Oct 2012
Phase 3
22
(Saizen® 0.057 mg/kg/Day)
efdynxudsj(rizwnujqof) = rmtovamcnb vpvcqjksgb (mlpdbgzmqs, 1.35)
-
10 Oct 2012
(Saizen® 0.035 mg/kg/Day)
efdynxudsj(rizwnujqof) = trdmsymijg vpvcqjksgb (mlpdbgzmqs, 1.15)
Not Applicable
56
Growth Hormone
(Recombinant Human Growth Hormone)
gaksfexjdj(epdanfflhx) = oczizeofhm ajxbmpfixn (gwenizidce, 6)
-
22 Jul 2010
placebo
(Placebo)
gaksfexjdj(epdanfflhx) = ymokyhdlfj ajxbmpfixn (gwenizidce, 4)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free